Literature DB >> 12217253

Optimizing blood pressure control in the obese patient.

Tobias Pischon1, Arya M Sharma.   

Abstract

Obesity is a major public health issue, and hypertension is one of the most common associated comorbidities. Current guidelines for optimal blood pressure levels in obese patients or for the treatment of obesity-hypertension do not provide specific recommendations that go beyond the rather general recommendation to lose weight. Based on the strong ties between obesity, hypertension, and type 2 diabetes, and the similarity of complications that occur in obesity-related hypertension and in hypertension associated with type 2 diabetes, it seems appropriate to explore the optimal blood pressure levels for obese hypertensive patients. Recently published studies underline the importance of weight reduction to reach this goal. Several lines of reasoning support the use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers as the appropriate first-line therapy in obese patients with uncomplicated hypertension. Nondihydropyridine calcium channel blockers, a-blockers, or low-dose diuretics may be added when necessary. Clearly, further studies are needed to define target blood pressure levels in obese patients and to clarify the value of established and newer drugs, like angiotensin receptor blockers, for the treatment of obese hypertensive patients. The role of antiobesity drugs in the management of the obese hypertensive patient also remains to be defined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217253     DOI: 10.1007/s11906-002-0064-8

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  70 in total

1.  Culturally-sensitive weight loss program produces significant reduction in weight, blood pressure, and cholesterol in eight weeks.

Authors:  J D Ard; R Rosati; E Z Oddone
Journal:  J Natl Med Assoc       Date:  2000-11       Impact factor: 1.798

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Body fat as a predictor of the antihypertensive effect of nifedipine.

Authors:  G Støa-Birketvedt; E Thom; J Aarbakke; J Florholmen
Journal:  J Intern Med       Date:  1995-02       Impact factor: 8.989

4.  Microalbuminuria in obese patients with or without hypertension.

Authors:  P Valensi; M Assayag; M Busby; J Pariès; B Lormeau; J R Attali
Journal:  Int J Obes Relat Metab Disord       Date:  1996-06

5.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 6.  Abnormal kidney function as a cause and a consequence of obesity hypertension.

Authors:  J E Hall; M W Brands; J R Henegar; E W Shek
Journal:  Clin Exp Pharmacol Physiol       Date:  1998-01       Impact factor: 2.557

7.  Dimorphic cardiac adaptation to obesity and arterial hypertension.

Authors:  F H Messerli; K Sundgaard-Riise; E D Reisin; G R Dreslinski; H O Ventura; W Oigman; E D Frohlich; F G Dunn
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

8.  Predicting sudden death in the population: the Paris Prospective Study I.

Authors:  X Jouven; M Desnos; C Guerot; P Ducimetière
Journal:  Circulation       Date:  1999-04-20       Impact factor: 29.690

9.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

10.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more
  1 in total

1.  Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension : a prospective, open-label study.

Authors:  Arya M Sharma; Peter Bramlage; Wilhelm Kirch
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.